Prognostic Value of Serum Neurofilament Light Chain for Disease Activity and Worsening in Patients With Relapsing Multiple Sclerosis: Results From the Phase 3 ASCLEPIOS I and II Trials.

Ziemssen T, Arnold DL, Alvarez E, Cross AH, Willi R, Li B, Kukkaro P, Kropshofer H, Ramanathan K, Merschhemke M, Kieseier B, Su W, Häring DA, Hauser SL, Kappos L, Kuhle J.

Open source

DOI
10.3389/fimmu.2022.852563
Published
2022-03-31
Container
Front Immunol
Publisher
Not recorded
Open access
yes

Credibility signals

uncertain Score 53/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.3389/fimmu.2022.852563,
  title = {Prognostic Value of Serum Neurofilament Light Chain for Disease Activity and Worsening in Patients With Relapsing Multiple Sclerosis: Results From the Phase 3 ASCLEPIOS I and II Trials.},
  author = {Ziemssen T and  Arnold DL and  Alvarez E and  Cross AH and  Willi R and  Li B and  Kukkaro P and  Kropshofer H and  Ramanathan K and  Merschhemke M and  Kieseier B and  Su W and  Häring DA and  Hauser SL and  Kappos L and  Kuhle J.},
  year = {2022},
  journal = {Front Immunol},
  doi = {10.3389/fimmu.2022.852563},
  url = {https://doi.org/10.3389/fimmu.2022.852563}
}

RIS

TY  - JOUR
TI  - Prognostic Value of Serum Neurofilament Light Chain for Disease Activity and Worsening in Patients With Relapsing Multiple Sclerosis: Results From the Phase 3 ASCLEPIOS I and II Trials.
AU  - Ziemssen T
AU  -  Arnold DL
AU  -  Alvarez E
AU  -  Cross AH
AU  -  Willi R
AU  -  Li B
AU  -  Kukkaro P
AU  -  Kropshofer H
AU  -  Ramanathan K
AU  -  Merschhemke M
AU  -  Kieseier B
AU  -  Su W
AU  -  Häring DA
AU  -  Hauser SL
AU  -  Kappos L
AU  -  Kuhle J.
PY  - 2022
JO  - Front Immunol
DO  - 10.3389/fimmu.2022.852563
UR  - https://doi.org/10.3389/fimmu.2022.852563
ER  - 

APA

T, Z., DL, A., E, A., AH, C., R, W., B, L., P, K., H, K., K, R., M, M., B, K., W, S., DA, H., SL, H., L, K., & J., K. (2022). Prognostic Value of Serum Neurofilament Light Chain for Disease Activity and Worsening in Patients With Relapsing Multiple Sclerosis: Results From the Phase 3 ASCLEPIOS I and II Trials.. Front Immunol. https://doi.org/10.3389/fimmu.2022.852563

Source records